Key facts
- Third Arc Bio’s last known valuation is $314.0M (Jan 2026).
- It has raised $249.7M across 1 recorded rounds; the latest was Later Stage VC ($72.5M) in Jul 2024.
- Notable investors include Andreessen Horowitz, Goldman Sachs Asset Management, Hillhouse Investment Group, T. Rowe Price Group, Foresite Capital — 20 tracked in total.
- Third Arc Bio has filed 1 Form D with the SEC, most recently Aug 2024 ($72.5M sold to 32 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 20 names
- ·Watchlist + deal alerts for Third Arc Bio
Funding rounds
1 roundsAbout Third Arc Bio
Operator of a biotech company intended to research multifunctional antibodies. The company's platform provides transformational therapies for solid tumors, inflammation, and immunology diseases in the form of multifunctional antibodies that create immune synapses to activate or inhibit T cells precisely, enabling medical companies with antibodies for immune system diseases.
- Sector
- Healthcare
- HQ
- Lower Gwynedd, PA, United States
- Founded
- 2022
- Employees
- 37
- Website
- thirdarcbio.com/
- Ownership
- Privately Held (backing)
Third Arc Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Third Arc Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Third Arc Bio in its N-PORT filings yet. We sweep new filings monthly.